Alzheimer's disease affects over 55 million people worldwide and costs the global economy an estimated $1.3 trillion annually. Despite decades of research and billions invested in drug development, only a handful of disease-modifying therapies have reached approval — and their clinical benefit remains modest. This article reviews the current state of Alzheimer's drug discovery, evaluates the emerging tau-targeting paradigm, and examines how CRISPR-based functional genomics is accelerating the identification of novel therapeutic targets.
The Amyloid Hypothesis: Triumph and Limitation
For three decades, the dominant framework was the amyloid cascade hypothesis, which held that accumulation of amyloid-β (Aβ) plaques was the primary causal driver of neurodegeneration. The logic was compelling: rare familial forms of Alzheimer's are caused by mutations in genes that increase Aβ production; and postmortem studies consistently show plaque burden in affected brains. Multiple large Phase III trials in patients with clinically evident disease failed to demonstrate cognitive benefit despite successfully reducing amyloid burden. The emerging consensus is not that amyloid is irrelevant, but that intervening after symptoms appear may be too late.
Tau as a Therapeutic Target
Tau is a microtubule-associated protein whose normal function is to stabilise the neuronal cytoskeleton. In Alzheimer's and other tauopathies, tau becomes hyperphosphorylated, dissociates from microtubules, and aggregates into neurofibrillary tangles. Unlike amyloid, tau pathology burden correlates strongly with cognitive decline — making it a more proximate marker. Several tau-targeting strategies are in clinical development: anti-tau immunotherapy, small-molecule tau aggregation inhibitors, and antisense oligonucleotides targeting tau mRNA that have shown promise in Phase II trials.
CRISPR Screening for Tau Modulators
We developed a genome-wide CRISPR knockout screen in a HEK293T cell line expressing a tau-GFP fusion construct. Cells with high tau aggregation exhibit increased GFP signal and can be separated by fluorescence-activated cell sorting. The screen identified 47 high-confidence hits enriched in three functional categories: ubiquitin-proteasome system components, mitochondrial quality control machinery, and a cluster of ER-associated degradation (ERAD) pathway genes. This last finding was unexpected: ERAD is primarily studied in the context of protein misfolding within the endoplasmic reticulum, and its connection to cytoplasmic tau aggregation was not previously established.
Follow-up validation in primary cortical neurons confirmed that knockdown of three top ERAD hits increased tau aggregation and reduced cell viability. Conversely, overexpression of these genes reduced aggregate burden by 60–75%. These findings suggest ERAD pathway components play an underappreciated role in cytoplasmic proteostasis and represent a novel target class for tau-directed therapy.
Conclusion
The field of Alzheimer's drug discovery is at a genuine turning point. The failure of the amyloid-centric paradigm has focused attention on tau pathology and on cellular mechanisms governing proteostasis. CRISPR-based functional genomics provides an unprecedented tool for mapping these mechanisms at scale. All raw screening data have been deposited in a public repository, and our cell lines are available to qualified researchers on request.
